Bracco Imaging S.p.a.

Bracco Suisse Sa

Bracco Diagnostics Inc.

Dyax Corporation

Bracco International Bv

Orchid Biosciences, Inc.

Other

Arroyo Biosciences, LLC

Rolf E Swenson

Palaniappa Nanjappan

Edmund R Marinelli

Kondareddiar Ramalingam

Karen E Linder

Bo Song

Philippe Bussat

Radhakrishna K Pillai

Sibylle Pochon

Adrian D Nunn

Mathew A Von Wronski

Hong Fan

Ajay Shrivastava

Luciano Lattuada

Michael F Tweedle

Aaron Sato

Daniel T Dransfield

Julius P Zodda

Janet L Gelbach

Aaron M Fontaine

Patrick M McDonald

Kathryn M Hunter

Stephen E Hidem

Christophe Arbogast

Natarajan Raju

Enrico Cappelletti

Bernard Lamy

Sharon Michele Walker

Hong (Helen) Fan

Feng Yan

Samir Cherkaoui

Sudha Khurana

Ramachandran S Ranganathan

Patrick M Mcdonald

Daniel D Darst

Robert Charles Ladner

Daniel J Sexton

Ernest Balestracci

Silvio Aime

Daniel Darst

Charles R Quirico

Eric Jason Krause

Pierfrancesco Morosini

Jacob S Childs

Vishal N Lokhande

Fulvio Uggeri

Chao Lin

Sheila H DeWitt

Giovanni Battista Giovenzana

Luisella Calabi

Camilla Cavallotti

Robert D Juncosa

Giovanni Palmisano

Massimo Sisti

Helen Fan

Dale Robert Pfost

Ramachandra Ranganathan

Linda Chaabane

Vito Lorusso

Mary Ellen Maddalena

Christoph De Haën

Ramalingam Kondareddiar

Radhakrishua Pillai

Sybille Pochon

Kimberly J McDaniel

Sheldon M Kugelmass

Gary J Schnerr

Edmund E Marinelli

Hong (helen) Fan

Hong Helen Fan

Kimberly J Mcdaniel

Aaron K Sato

Methods for setting up, maintaining and operating a radiopharmaceutical infusion system, that includes a radioisotope generator, are facilitated by a computer of the system. The computer may include pre-programmed instructions and a computer interface, for interaction with a user of the system, for example, in order to track contained volumes of eluant and/or eluate, and/or to track time from completion of an elution performed by the system, and/or to calculate one or more system and/or injection parameters for quality control, and/or to perform purges of the system, and/or to facilitate diagnostic imaging.

Integrated strontium-rubidium radioisotope infusion systems

Infusion system configurations and assemblies facilitate routing of infusion circuit tubing lines. Tubing lines are routed into and out from compartments of a shielding assembly for the infusion system, at locations which prevent kinking and/or crushing of the lines, and/or provide for ease in assembling the circuit. A plurality of the lines may be held together by a support frame to form a disposable infusion circuit subassembly, that can further facilitate routing of the lines.

Infusion system configurations

Integrated Strontium-Rubidium radioisotope infusion systems

The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1Pantagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1Pantagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

Sphingosine 1-phosphate receptor antagonists

Methods for setting up, maintaining and operating a radiopharmaceutical infusion system, that includes a radioisotope generator, are facilitated by a computer of the system. The computer includes pre-programmed instructions and a computer interface, for interaction with a user of the system, for example, in order to track contained volumes of eluant and/or eluate, and/or to track time from completion of an elution performed by the system, and/or to calculate one or more system and/or injection parameters for quality control, and/or to perform purges of the system, and/or to facilitate diagnostic imaging.

Infusion systems including computer-facilitated maintenance and/or operation and methods of use

The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides.

KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.

Targeting vector-phospholipid conjugates

The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel peptides able to bind fibrin, to a process for their preparation and to compositions thereof for use in therapy and diagnostics. The compounds of the invention bind, in particular, to fibrin present in the extracellular matrix (EC) of tumor or connective tissue of stroma thus acting as targeting moieties able to bring and successfully bound an active moiety linked thereto to fibrin depositions inside solid tumors.

Fibrin binding peptide conjugates for diagnostic and therapeutic applications

Infusion system with radioisotope detector

Radioisotope generator system including activity measurement and dose calibration

Growing community of inventors

Princeton, NJ, United States of America

Rolf E Swenson